Gemzar News and Research

RSS
Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Nuvilex discusses Cell-in-a-Box technology used for pancreatic cancer clinical trial

Nuvilex discusses Cell-in-a-Box technology used for pancreatic cancer clinical trial

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity third quarter total revenue increases marginally to $23.3 million

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting

OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting

P&G, Teva sign partnership agreement for consumer health care

P&G, Teva sign partnership agreement for consumer health care

Survey: AR symptoms continue to impact patients' daily activities

Survey: AR symptoms continue to impact patients' daily activities

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva fourth quarter net sales increase 16% to record $4.4 billion

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC